We have been conducting research on regeneration of the damaged central nervous system, which includes (i) regrowth of the disrupted neuronal axons, (ii) replenishment of lost neural cells, and (iii) recovery of lost neural functions. In particular, we have investigated cell therapy for treating spinal cord injury. Considering the ethical issues related to fetal cells and embryonic stem cells, there is increasing interest in stem cell technology involving induced pluripotent stem (iPS) cells. Here, we wish to introduce our achievements in iPS cell-based therapy. In addition to their application for cell therapy, iPS cell technologies provide versatile tools for investigation of the pathophysiology of various diseases. Indeed, disease model mice do not always recapitulate the pathophysiology of human diseases. However, iPS cell technology can provide some solutions because neural cells at various developmental stages and a wide variety of cells with the same genetic information as that of patients can be obtained for further investigation. Through these investigations, I have had numerous collaborations with life science industries, including pharmaceutical companies, and generated various patents. Some examples of these achievements will be discussed here.
Before introducing the details of our past and on-going research, I wish to introduce the concepts of regeneration of the CNS, which include (i) regrowth of disrupted neuronal axons, (ii) replenishment of lost neural cells, and (iii) recovery of lost neural functions. Investigation of CNS regeneration is indeed an exciting and profound research fi eld, but also provides enormous opportunities for industry-university cooperation. In fact, through investigations of CNS regeneration and stem cell biology, I have obtained 30 patents and fi led 57 patents pending.
(i) Regrowth of disrupted neuronal axons Axonal regeneration hardly takes place in the damaged CNS because of the presence of large amounts of inhibitors [ 9, 10 ] , including myelin-derived proteins (e.g. MAG, Nogo-A, and OMgp) [12] [13] [14] [15] [16] [17] , and glial scar-derived factors (e.g. CSPG) [ 18, 19 ] , and extracellular matrix-derived factors (e.g. semaphorins). In a previous collaboration with Dainippon Sumitomo Pharma Co. Ltd., we demonstrated the therapeutic effects of a speci fi c inhibitory compound (SM-216289) against semaphorin3A (Sema3A) [ 20 ] , a major inhibitor of axonal regeneration [21] [22] [23] , in spinal cord injury (SCI) using a rat complete transection model. Remarkably, we found that this Sema3A inhibitor induced signi fi cant functional recovery as well as enhanced axonal regeneration at the lesion site and robust Schwann cell-mediated myelination. This evidence suggests the possibility of using Sema3A inhibitors for the treatment of human SCI patients in the future, which is being continuously investigated through the collaboration between our group at Keio University and Dainippon Sumitomo Pharma Co. Ltd. In addition to treatment of SCI, we found another application of the Sema3A inhibitor in the ophthalmological fi eld. In collaboration with the Department of Ophthalmology at Keio University School of Medicine and Dainippon Sumitomo Pharma Co. Ltd., we showed that the Sema3A inhibitor was able to treat peripheral nerve damage of the cornea. Treatment with the Sema3A inhibitor promoted a robust network of regenerating nerves as well as functional recovery of corneal sensation through subconjunctival injections in a mouse keratoplasty model [ 24 ] , suggesting a novel therapeutic strategy for treating peripheral nerve damage of the cornea.
(ii) Replen fi shment of lost neural cells It is obvious that replenishment of lost neural cells will be a very important aim of stem cell technology. In our previous studies [25] [26] [27] [28] [29] [30] , we found that transplanted neural stem cells (NSCs) survived and differentiated into neurons, astrocytes, and oligodendrocytes, which are three major cellular components of the CNS. Graft-derived neurons formed synapses with host neurons and integrated with host neuronal circuits. Graft-derived oligodendrocytes were shown to participate in re-myelination of host axons in SCI models [ 28, 30 ] , which signi fi cantly contributes to functional recovery after SCI [ 30 ] . It is possible that graft-derived astrocytes and undifferentiated NSCs produce various trophic factors that support angiogenesis [27] [28] [29] , cellular survival, and axonal regeneration of host axons including 5-HT-positive raphe-spinal tracts involved in the locomotive functions of hindlimbs [27] [28] [29] . Thus, these fi ndings suggest that both cellular replacement mechanisms and trophic mechanisms are responsible for the effects of stem cell therapy in SCI models. The details of stem cell therapy for treating SCI will be described in the later sections.
(iii) Recovery of lost neural functions Considering the therapeutic applications of stem cells, it is obvious that recovery of lost neural functions is an important aspect of regeneration of the damaged CNS. For functional recovery, we are interested in rehabilitation and its combination with blockade of the inhibitors of axonal regeneration [ 31 ] , and/or stem cell transplantation. 
Basic Biology and Tools for Investigation of NSCs
It is understood that (i) speci fi c immunocytochemical markers, (ii) selective culture methods, and (iii) technologies for the prospective identi fi cation and isolation of NSCs and early precursor cells (neural stem/precursor cells, NS/PCs) have greatly contributed to the rapid progress of the investigation of NSCs [ 8 ] .
(i) Speci fi c immunocytochemical markers Speci fi c marker molecules for NSCs include Musashi1 (an RNA-binding protein) [32] [33] [34] [35] [36] [37] [38] , nestin [ 39, 40 ] , and some Sox family transcription factors [ 41 ] .
(ii) Selective culture methods The neurosphere method involves suspension culture with fi broblast growth factor-2 (FGF-2) and/or epidermal growth factor in a de fi ned medium [ 42 ] , which has been widely used as a versatile method for selective expansion of NSCs. Neurosphere culture allowed us to expand NSCs in an undifferentiated state. NS/PCs obtained by neurosphere culture have been used for transplantation into patients with SCI and Parkinson's disease. We applied neurosphere culture for ef fi cient induction of NSCs from pluripotent stem cells including embryonic stem (ES) cells and induced pluripotent stem (iPS) cells [43] [44] [45] . Brie fl y, we generated embryoid bodies (EBs) from mouse ES/ iPS cells in the presence of neural inducers (noggin or retinoic acid), resulting in neurally biased differentiation of ES cells and a substantial number of NSCs. The NSCs within EBs were then expanded in the presence of FGF-2 to give rise to primary neurospheres that were subsequently passaged to form secondary neurospheres. Interestingly, when we induced the differentiation of primary neurospheres, they exclusively gave rise to neurons, but not glial cells. The majority of neurons derived from primary neurospheres were early projection neurons including forebrain type cholinergic neurons, mesencephalic dopaminergic neurons and spinal motor neurons. However, when we induced the differentiation of secondary neurospheres, they gave rise to neurons, astrocytes, and oligodendrocytes. Neurons derived from secondary neurons, including GABAergic interneurons as the major population, were different from those derived from primary neurospheres. Furthermore, tertiary neurospheres gave rise to a higher proportion of glial cells. Therefore, this in vitro differentiation system of mouse pluripotent stem cells probably recapitulates the change of differentiation potential of NSCs, which occurs in vivo [ 46 ] . Using these methods for neural differentiation of pluripotent stem cells, we generated patents, including "Process for Producing Nerve Stem Cells, Motor Neurons, and GABAergic Neurons from Embryonic Stem Cells," and "Remedy for Dysmnesia," and licensed out these patents and related technologies to various pharmaceutical companies and bio-ventures.
(iii) Technologies for the prospective identi fi cation and isolation of NSCs and early precursor cells For the prospective identi fi cation of NSCs, combinations of antibodies against cell surface antigens [ 47, 48 ] and NSC-speci fi c fl uorescence reporters [49] [50] [51] [52] [53] [54] [55] [56] have been used [ 8 ] . For the latter strategy, we constructed a reporter gene consisting of cDNA encoding a fl uorescent protein (green fl uorescent protein, Venus, Kusabira Orange, or ffLuc-cp156 [ 57 ] ), which was placed under the control of the 2nd intronic enhancer of the nestin gene or enhancer elements of the Musashi1 gene for speci fi c expression in NSCs. By taking advantage of these strategies using cell type-speci fi c promoter/enhancer elements and fl uorescent reporter genes, we generated several patents for the prospective identi fi cation and isolation of NSCs ("Enriched Preparation of Human Fetal Multipotential Neural Stem Cells") and dopaminergic neurons ("Method of Concentrating and Separating DOPAMINergic Neurons") [ 58 ] . In addition to (i)-(iii), there are rapidly accumulating studies of the signaling mechanisms involved in the self-renewal and differentiation of NSCs. In the related fi eld, we have published numerous scienti fi c reports and generated various patents including "Numb Protein Expression Inhibitor Making Use 
Stem Cell Therapy for Treating SCI

Pathophysiology of SCI
The pathophysiology of SCI is known to change over time after the initial injury. SCI is initiated by primary mechanical trauma (the so called "primary injury") and followed by a series of secondary events (the so called "secondary injury") [ 8 ] . The secondary injury includes hemorrhage, ischemia, and hypoxia (which take place within seconds), production of pro-in fl ammatory cytokines and glutamate cytotoxicity (which take place within minutes), and production of free radicals and nitric oxide, protease activation, and neutrophil invasion (which take place within hours). These events characterize the strong in fl ammation at the acute phase of SCI. The acute phase of SCI lasts for several days after the primary mechanical trauma, which is followed by delayed events (the so called "subacute phase") including neural apoptosis, astrogliosis, and axonal demyelination. The subacute phase is followed by an irreversible stage (the so called "chronic phase") including severe axonal degeneration, cyst formation, and permanent loss of spinal functions. The chronic phase is considered to begin at 6 weeks in rodents and 6 months in humans after the primary mechanical trauma. This phenomenon is not observed in salamanders in which the spinal cord regrows even after tail amputation [ 59 ] . The damaged spinal cord hardly regenerates in adult mammalian animals because of limited activation of endogenous stem cells and axonal regeneration, which is why there is a need for blockade of the inhibitors of axonal regeneration, and transplantation of NSCs for treating the SCIs of humans.
Interventions at the Acute Phase
In the acute phase of SCI, in fl ammatory cells such as neutrophils, hematogenous macrophages (blood-borne macrophages), and resident microglia accumulate at the lesion site. Because pro-in fl ammatory cytokines such as tumor necrosis factor a , interleukin (IL)-1 b , and IL-6 are major regulators of in fl ammation, these cytokines are likely targets for potential pharmaceutical interventions for treating SCI [ 60 ] . Among them, IL-6 induces the activation and invasion of microglia/macrophages within SCIs. Thus, in collaboration with Chugai Pharmaceutical Co. Ltd, we administered an anti-mouse IL-6 receptor antibody, MR16-1, to a mouse SCI model, resulting in improved functional recovery with reduced in fl ammation and astrogliosis, and enhanced tissue sparing [ 61 ] . Furthermore, we have investigated the mechanism of action of the anti-MR16-1 in more detail by focusing on the effect of temporary inhibition of IL-6 signaling in macrophages and microglia after SCI [ 60 ] . We found that MR16-1 treatment reduced the in fi ltration of macrophages, but increased the number of microglia at the SCI. Thus, temporary inhibition of IL-6 signaling must have induced switching of the major in fl ammatory cell type at the lesion from hematogenous macrophages to resident microglia, resulting in improved tissue sparing and debris clearance for promotion of neural repair after SCI. Notably, a humanized antibody against the human IL-6 receptor (Actemra; tocilizumab) is already used clinically, and our fi ndings suggest its potential application for the treatment of SCI patients at the acute phase. Keio University and Chugai Pharmaceutical Co. Ltd have fi led patents covering the therapeutic actions of blocking antibodies against IL-6 signaling during the acute phase of SCI ("Therapeutic Agent for Spinal Cord Injury Comprising Interleukin-6") in various countries.
Stem Cell Transplantation at the Sub-acute Phase
Considering the time course of secondary injury, the most appropriate time point for transplantation of NSCs is important. In rodent SCI models, we performed transplantation of NS/PCs at 9 days after injury, i.e., after the acute in fl ammatory phase and before the astroglial scar becomes prominent [ 8 ] . In mice, we found that transplantation of NS/PCs at the chronic phase did not result in functional recovery [ 62 ] . Thus, the chronic phase of SCI is not appropriate for therapeutic transplantation. The formation of large cysts and the development of glial scarring during the chronic phase might inhibit axonal regeneration (Nishimura et al. Submitted). In the case of humans and considering the time course of in fl ammation, it is assumed that NS/PCs should be transplanted by 4 weeks after the primary mechanical trauma. In relation to stem cell therapy of SCIs, we generated a patent entitled "Central Nervous System Neural Progenitor Cell which Induces Synapse-Forming Neurons in the Spinal Cord."
Non-human Primate Models of SCI
While most studies of SCI have used rodent models, it is not easy to directly correlate the results obtained in rodent models to clinical cases because of the functional and anatomic differences of the spinal cord between rodents and primates. Previously, we developed a non-human primate model of contusive SCI at the C5 level in the common marmoset. This model consisted of mild, moderate and severe contusive SCIs that were induced by dropping one of three different weights (15, 17, or 20 g ) onto the C5 level from a height of 50 mm. We also developed behavioral assays to monitor the motor functions of these common marmoset models of SCI by measurements of spontaneous motor activity, as well as bar grip and cage climbing tests [ 63 ] . Using this model, we veri fi ed the therapeutic effects of transplantation of human fetal NSCs [ 64 ] and infusion of hepatocyte growth factor (HGF) [ 65 ] . By con fi rming the safety and utility in this non-human primate model, we initiated a Phase 1 clinical trial of HGF infusion for treatment of patients with amyotrophic lateral sclerosis in collaboration with Professor Masashi Aoki at Tohoku University and Kringle Pharma Co Ltd. [ 66 ] . We also fi led a patent for the common marmoset model of SCI in both Japan and the USA ("Method of Constructing Spinal Injury Model Monkey and Utilization Thereof").
Sources of Stem Cells for Treating SCI
We have demonstrated that transplantation of human fetal NSCs into a common marmoset model of SCI results in signi fi cant functional recovery. However, because of the ethical controversies, we are not allowed to perform clinical trials using fetal cells. Human ES cells are also somewhat controversial. Therefore, we became interested in iPS cell-derived NS/PCs, directly induced NSCs [ 67 ] , and neural crest stem cells [ 68 ] for transplantation into patients. These cells can be derived from adult tissues, including a patient's own tissue, and are therefore not ethically controversial.
iPS Cell-Based Therapy for Treating SCI
Brief Summary of iPS Cell Technology
iPS cell technology was developed by Professor Shinya Yamanaka, the 2012 Nobel laureate for Physiology or Medicine, and colleagues at Kyoto University. In 2006, they published a study showing that somatic cells, such as adult skin fi broblasts, can be reprogrammed into ES cell-like pluripotent stem cells by retroviral transduction of four genes encoding transcription factors, i.e., Oct4 , Sox2 , Klf4 , and c-Myc [ 69 ] . Since 2006, we have had a close collaboration with the Yamanaka Laboratory, aiming for iPS cell-based therapy for treating SCI patients. In 2007, establishment of human iPS cells using retroviral or lentiviral transduction of reprogramming factors was reported by Yamanaka [ 70 ] and Thomson [ 71 ] . Subsequently, various methods have been published (reviewed by Okano [ 72 ] for generating integration-free iPS cells, including episomal vectors, the Sendai viral vector, and modi fi ed RNA).
Transplantation of NSCs Derived from iPS Cells
First, we examined transplantation of NSCs derived from mouse iPS cells into a mouse SCI model. However, the investigation was not as straightforward as we had expected. We had already established mouse ES cells [ 43, 44 ] , and induced various mouse iPS cell lines into secondary neurospheres. The resultant mouse iPS cell-derived secondary neurospheres gave rise to neurons, astrocytes, and oligodendrocytes, which was irrespective of their somatic origin or method of iPS cell production [ 45 ] , in a similar manner as that of mouse ES cell-derived secondary neurospheres. However, when we transplanted these mouse iPS cell-derived secondary neurospheres into mouse brains, varying tumorigenic propensities were observed depending on the somatic origin of the iPS cells [ 45 ] . These observations indicated that epigenetic memory and completeness of reprogramming were involved in the tumorigenic propensities of iPS cell-derived NSCs. Subsequently, we transplanted non-tumorigenic iPS cell-derived NSCs (primary or secondary neurospheres) into mouse thoracic contusion injury models (Th10) to examine their therapeutic effects.
Interestingly, we found that transplantation of secondary neurospheres, but not primary neurospheres, resulted in signi fi cant and long-lasting functional recovery, indicating the importance of glial cells. We found that transplanted iPS cell-derived secondary neurospheres gave rise to neurons, astrocytes, and oligodendrocytes, and re-myelination was induced by graft-derived oligodendrocytes. Conversely, transplantation of tumorigenic iPS cell-derived secondary neurospheres into SCI model mice resulted in functional recovery, but the effects were transient. Eventually, transplanted animals suffered from strong paralysis due to the effects of tumors. Thus, the safety issue concerning tumorigenicity is crucial for iPS cell-based therapy of SCI.
Human iPS cells can be induced to differentiate into NSCs in a similar manner as that of mouse iPS cells, although additional passage(s) are required to obtain both neurons and glia from iPS cell-derived neurospheres. Thus, in the case of humans, we used tertiary neurosphere instead of secondary neurospheres for the following transplantation experiments. We screened human iPS cell lines and found that NSCs derived from the 201B7 human iPS cell line were non-tumorigenic (Okada et al., submitted). We transplanted 201B7 human iPS cell-derived NSCs into mouse [ 29 ] and common marmoset SCI models (Kobayashi et al., submitted), and found that grafted cells gave rise neurons, astrocytes, and oligodendrocytes and induced functional recovery without any signs of tumorigenesis.
Future Direction of Cell Therapy for Treating SCI Using Reprogramming Technologies
Thus far, we have transplanted NSCs derived from mouse and human iPS cells into mouse and non-human primate SCI models, which results in functional recovery. Furthermore, using appropriate cell lines, there were no signs of tumorigenesis in transplanted animals during the time course of the observation. For clinical application in the future, there are some concerns that need to be addressed. Considering that the critical time window for transplantation is within 4 weeks after SCI (primary mechanical trauma) and establishment of human iPS cells and subsequent induction of NSCs, which produce both neurons and glia, requires ~180 days, it is essential to prepare clinical grade banks (or stocks) of iPS cells and iPS cell-derived NSCs in advance. Clinical grade cell banks would allow these cells to be transplanted into any patient within the critical period. In addition, before iPS cellbased therapy can be used in the clinic, we believe that the safety issues should be addressed as follows: (1) usage of integration-free iPS cells, (2) selection of an appropriate neural differentiation method, (3) selection of appropriate iPS cell clones by somatic origin, reprogramming, epigenetic characterization, and fl ow cytometric analysis, (4) pre-evaluation of tumorigenesis in vivo, and (5) elimination of graft-derived tumors [ 72 ] .
Disease Models
There is increasing interest in iPS cell-based modeling of diseases [ 73 ] . In fact, disease model mice do not always recapitulate the pathophysiology of human diseases. Furthermore, it is extremely dif fi cult to investigate what is taking place in vivo during the onset of disease, particularly neurological and psychiatric diseases, partly because there is poor accessibility to pathological foci in the brain. These aspects complicate the investigation of human neurology. However, iPS cell technology can provide some solutions because neural cells at various developmental stages and a wide variety of cells with the same genetic information as that of patients can be obtained for further investigation. In my laboratories, we have been characterizing various neurological and psychiatric diseases that are classi fi ed into the following categories: (1) diseases caused by disrupted gene regulation, (2) diseases caused by structural abnormalities of the nervous system, (3) diseases caused by abnormal neural functions, (4) diseases caused by abnormal metabolism in the nervous system, and (5) late-onset neurological diseases including Alzheimer's disease [ 74 ] and Parkinson's disease [ 75 ] . Characterization of iPS cells derived from pediatric neurological disorders may recapitulate disease processes, at least partially, which may contribute to drug development and future therapies.
